Goldman Sachs
May 28, 2026
MiniMed Group Previewing 4QFY26 and FY27 Guidance
Single Stock ReportEquitiesHealth Care
Goldman Sachs previews MiniMed's first standalone earnings report, citing complex reporting mechanics post-IPO and projecting a revenue growth lead in OUS markets.
Key Takeaways
- 1.MiniMed is reporting its first standalone quarter on June 3, but the split-period reporting (1 month Medtronic, 2 months standalone) will make headline P&L comparison difficult.
- 2.Reported 4Q results will be impacted by a $157 million milestone payment to Blackstone for the early approval of MiniMed Flex.
- 3.Analysts view MMED shares as meaningfully dislocated at current valuation levels (0.83x CY26 sales) despite recent post-IPO underperformance.
Table of Contents
- Valuation & Risks
- Disclosure Appendix
- GS Factor Profile
- M&A Rank
- Quantum
- Disclosures
- Company-specific regulatory disclosures
- Distribution of ratings/investment banking relationships
- Price target and rating history chart(s)
- Target price history table(s)
- Regulatory disclosures
- Ratings, coverage universe and related definitions
- Global product; distributing entities
- General disclosures
Document Preview
Access the Full Report
Get unlimited access to institutional research reports with a 14-day free trial.
Authors
David RomanJamie PersePhilip CooverJenny RabinowitzMarco Espaillat
Securities
MMEDMedtronicRTY
Themes
Post-IPO Financial TransitionMedTech Product CatalystsGLP-1 Market Disruption Risks
Regions
North AmericaOtherUnited States